New aspects of autoantibody diagnostics in connective tissue diseases;Neue aspekte der autoantikörper-diagnostik bei kollagenosen

Zeitschrift fur Rheumatologie

Volumn 61, Issue 4, 2002, Pages 355-366

  Mierau, Rudolf ^a   Genth, Ekkehard ^a  

^a Rheumaklinik   (Germany)

Author keywords

Autoantibodies; Connective tissue diseases; Myositis; Sj gren's syndrome; Systemic lupus erythematodes; Systemic sclerosis

Indexed keywords

AUTOANTIBODY;

ANTIBODY DETECTION; ARTICLE; CLINICAL EXAMINATION; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; LABORATORY DIAGNOSIS; MYOSITIS; SCLERODERMA; SENSITIVITY AND SPECIFICITY; SJOEGREN SYNDROME; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODY SPECIFICITY; AUTOANTIBODIES; COLLAGEN DISEASES; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; PREDICTIVE VALUE OF TESTS;

EID: 0036690734     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-002-0430-6     Document Type: Article

References (91)

1. Preliminary criteria for the classification of systemic sclerosis (scleroderma)
2. Polymyositis and dermatomyositis
3. The 1982 revised criteria for the classification of systemic lupus erythematosus
4. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus
5. Preliminary criteria for the classification of Sjögren's Syndrome
6. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome - Report of an international workshop
7. A new approach to the classification of idiopathic inflammatory myopathy: Myositis-specific autoantibodies define useful homogeneous patient groups
8. Klinische bedeutung von autoantikörpern
9. Rheumatic disease syndromes associated with antibodies to the Ro (SS-A) ribonuclear protein
10. Autoantibodies in polymyositis
11. Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy
12. The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies
13. Prevalence and clinical relevance of 52-kDa and 60-kDa Ro/SS-A autoantibodies in Japanese patients with systemic sclerosis
14. Undifferentiated connective tissue disease with antibodies to Ro/SSA: Clinical features and follow-up of 148 patients
15. Rheumatoid arthritis: Anti-Ro antibodies define a non-HLA-DR4 associated clinicoserological cluster
16. Differential recognition of the 52-kd Ro(SS-A) antigen by sera from patients with primary biliary cirrhosis and primary Sjogren's syndrome
17. Autoantibodies reactive with Ro(SSA) and La(SSB) and pregnancy
18. Coexistence of anti-topoisomerase 1 and anti-centromere antibodies in patients with systemic sclerosis
19. Anticentromere antibodies in subjects with no apparent connective tissue disease
20. Clinical correlation of anticentromere antibodies
21. High prevalence of antibodies to recombinant CENP-B in primary biliary cirrhosis: Nuclear immunofluorescence patterns and ELISA reactivities
22. Clinical significance of anticentromere antibodies in patients with systemic lupus erythematosus
23. Clinical and laboratory features of anticentromere antibody positive primary Sjogren's syndrome
24. Anti-Scl-70 antibodies detected by immunoblotting in progressive systemic sclerosis: Specificity and clinical correlations
25. Anti-topoisomerase I (Anti-Scl-70) antibodies in patients with systemic lupus erythematosus
26. Antihistone antibodies in patients with localized scleroderma
27. Anti-U3 snRNP antibodies in localised scleroderma
28. Anti-U1RNP antibodies in patients with localized scleroderma
29. Coexistence of two antisynthetases in a patient with the antisynthetase syndrome
30. Human leucocyte antigen typing in rheumatoid arthritis/polymyositis overlap syndrome
31. Structures targeted by the immune system in myositis
32. Classification criteria for the idiopathic inflammatory myopathies
33. Classification of anti-endothelial cell antibodies into antibodies against microvascular and macrovascular endothelial cells: The pathogenic and diagnostic implications
34. Western-blotting method for detecting antibodies against human muscle contractile proteins in myositis
35. Novel autoantibodies against muscle-cell membrane proteins in patients with myositis
36. Autoantibody to the nucleosome subunit (H2A-H2B)-DNA is an early and ubiquitous feature of lupus-like conditions
37. The key role of nucleosomes in lupus
38. Anti-subnucleosome reactivities in systemic lupus erythematosus (SLE) patients and their first-degree relatives
39. The central role of chromatin in autoimmune responses to histones and DNA in systemic lupus erythematosus
40. Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases - Antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus
41. Nucleosomes are major T and B cell autoantigens in systemic lupus erythematosus
42. Nachweis von anti-nukleosomen-antikörpern bei patienten mit SLE, systemischer sklerose und kontrollkollektiven. Vergleich von 4 ELISA-Systemen
43. Failure to detect antinucleosome antibodies in scleroderma: Comment on the article by Amoura et al
44. Serologic abnormalities in systemic sclerosis
45. Systemic sclerosis: An autoantibody mosaic
46. Autoantibodies to RNA polymerases recognize multiple subunits and demonstrate cross-reactivity with RNA polymerase complexes
47. Korrelation von klinischen merkmalen mit dem nachweis verschiedener autoantikörper bei patienten mit systemischer sklerose
48. Identification of alpha-fodrin as a candidate autoantigen in primary Sjogren's syndrome
49. Anti-alpha-fodrin antibodies in Sjogren syndrome and lupus erythematosus
50. IgA and IgG autoantibodies against alpha-fodrin as markers for Sjogren's syndrome
51. Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjogren's syndrome
52. Up-regulation of M3-muscarinic receptors in labial salivary gland acini in primary Sjogren's syndrome
53. Use of muscarinic agonists in the treatment of Sjogren's syndrome
54. Autoantibodies as predictors of disease
55. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: A six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting
56. Prognostic significance of anticentromere antibodies and antitopoisomerase I antibodies in Raynaud's disease
57. The role of an autoantigen, histidyl-tRNA synthetase, in the induction and maintenance of autoimmunity
58. Antinuclear antibodies heralding the onset of systemic lupus erythematosus
59. Range of antinuclear antibodies in "healthy" individuals
60. Development of anti-dsDNA autoantibodies prior to clinical diagnosis of systemic lupus erythematosus
61. Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus
62. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus
63. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus
64. The utility of immunologic laboratory tests in patients with rheumatic diseases
65. The association between antiribosomal P antibodies and active nephritis in systemic lupus erythematosus
66. A close temporal relationship of liver disease to antiribosomal P0 protein antibodies and central nervous system disease in patients with systemic lupus erythematosus
67. Prevalence of autoantibodies to ribosomal P proteins in juvenile-onset systemic lupus erythematosus compared with the adult disease
68. Production of anti-Ro/SS-A and anti-La/SS-B autoantibodies is closely coordinated in systemic lupus erythematosus and independent of anti- dsDNA production
69. Analysis of epitope spreading over an eleven-year period in a patient with systemic lupus erythematosus
70. Ro/SS-A and La/SS-B antibody level variation in patients with Sjogren's syndrome and systemic lupus erythematosus
71. Fluctuation of anti-Ro/SS-A antibody levels in patients with systemic lupus erythematosus and Sjogren's syndrome: A prospective study
72. Enzyme-linked immunosorbent assay using isolated (U) small nuclear ribonucleoprotein polypeptides as antigens to investigate the clinical significance of autoantibodies to these polypeptides
73. IgG and IgM anti-snRNP reactivity in sequentially obtained serum samples from patients with connective tissue diseases
74. Long-term outcome in mixed connective tissue disease
75. A long-term longitudinal isotypic study of anti-topoisomerase I autoantibodies
76. Marker antibodies in scleroderma and polymyositis: Clinical associations
77. Longitudinal study of anticentromere and antitopoisomerase-I isotypes
78. Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis
79. A long-term longitudinal study of anticentromere antibodies
80. Three human chromosomal autoantigens are recognized by sera from patients with anti-centromere antibodies
81. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes
82. Origin and regulation of a disease-specific autoantibody response
83. Mi-2-Antikörper als verlaufsparameter bei dermatomyositis
84. Autoantikörper gegen SRP - Charakterisierung von 4 patienten
85. The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl
86. Anti-Ro/SSA antibodies and congenital heart block: Necessary but not sufficient
87. Antinuclear antibody screening in this new millennium: Farewell to the microscope?
88. Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens
89. A practical guide for serologic evaluation of autoimmune connective tissue diseases
90. Autoantibodies to extractable nuclear antigens: Making detection and interpretation more meaningful
91. Humoral immunity in polymyositis/dermatomyositis